

Thank you for joining us – the
webinar will start shortly

Setting mortality improvements with post-pandemic data

Emerging signals, or too early to tell?

Thursday 2nd April 2026

8am PT / 11am ET / 4pm UK



[linkedin.com/company/club-vita](https://www.linkedin.com/company/club-vita)



www.clubvita.net

Today's panel



Chair

Natalie Gleed FIA FSA
Head of Business
Development




Panellist

Erik Pickett PhD FIA FSA
Head of Actuarial
Content




Panellist

Nick Chadwick FIA
Longevity risk specialist



Agenda


1. How far off the pre-COVID trend is emerging data?
2. Can we use pandemic data to set post-pandemic improvements?
3. What happens if we just ignore the COVID years?



Poll question

Based on our calculations, US men in 2020 had the highest excess mortality in a single year of the pandemic. Which group do you think had the second highest excess mortality peak?

- UK men (in 2020)
- US women (in 2020)
- Dutch men (in 2020)
- US men (in 2021)
- Canadian men (in 2022)




Question 1:
How far off the pre-COVID trend is emerging data?





Pre-pandemic trend (UK)

UK Male SMRs (ages 65 to 95)




UK Female SMRs (ages 65 to 95)







What happened next? (UK)

UK Male SMRs (ages 65 to 95)




UK Female SMRs (ages 65 to 95)





Pre-pandemic trends (US)



US Male SMRs (ages 65 to 95)




US Female SMRs (ages 65 to 95)




What happened next? (US)



US Male SMRs (ages 65 to 95)



US Female SMRs (ages 65 to 95)




At the population level, COVID hit hardest in 2020, with excess almost as high in 2021, then halving in 2022. 2024 mortality almost back to trend for men, still high for women





Pre-pandemic trends (Canada)



Canada Male SMRs (ages 65 to 95)




Canada Female SMRs (ages 65 to 95)






What happened next? (Canada)

Canada Male SMRs (ages 65 to 95)




Canada Female SMRs (ages 65 to 95)



COVID peak delayed until 2022 in Canada and excess (or new normal) is persisting. 2024 mortality still higher than pre-pandemic trends.


Source: Club Vita calculations using CMI_2024 v05 projections model. Canadian data up to 2023 from the Human Mortality Database (www.mortality.org), 2024 data estimated using [StatisticsCanada life table](https://www150.statcan.gc.ca/n1/pub/82-625-x/2024001/article/00001-eng.htm). Note: 1.3% long term rate of improvement is used throughout





Pre-pandemic trends (Netherlands)



NL Male SMRs (ages 65 to 95)




NL Female SMRs (ages 65 to 95)




What happened next? (Netherlands)



NL Male SMRs (ages 65 to 95)



NL Female SMRs (ages 65 to 95)



Mortality rates have been stubbornly high in the Netherlands (versus pre-COVID expectations) since 2020.



Observations


- Most significant excess mortality experienced in the 2020-2022 period
- UK men, UK women, US men
Mortality rates back down to pre-pandemic expectations by c2024

Are we now stably back to pre-pandemic trends?
Or could we be witnessing a survivorship effect?

- US women, Netherlands men, Netherlands women, Canadian men, Canadian women
Latest mortality data not (yet) back to pre-pandemic expectations

Is this 'excess mortality' that will reduce in time?
Or is a 'new normal' emerging?

Each new year of data gives vital information



Question 2:
Can we use pandemic data to set
post-pandemic improvements?


The development of the CMI's “fitted overlay” methodology






CMI approach to COVID: CMI_2020 / 2021

UK Male SMRs (ages 65 to 95)



UK Female SMRs (ages 65 to 95)




CMI_2020 and CMI_2021 put zero weight on post 2019 data via “W” parameter. Pushing out the long-term rate leads to a slightly weaker projection.






CMI approach to COVID: CMI_2022


UK Male SMRs (ages 65 to 95)



UK Female SMRs (ages 65 to 95)




**CMI_2022 was first version to allow for post-COVID data in fitted trend.
25% weight placed on 2022 data via “W” parameter.**






CMI approach to COVID: CMI_2023

UK Male SMRs (ages 65 to 95)



UK Female SMRs (ages 65 to 95)




Approach modified for CMI_2023.
15% weight placed on 2022 and 2023 data via “W” parameter.




CMI approach to COVID: CMI_2024



UK Male SMRs (ages 65 to 95)




UK Female SMRs (ages 65 to 95)



CMI_2024 introduced a “Fitted Overlay” to directly model COVID excess mortality. Core calibration assumes excess mortality to half each year after a peak in 2020.


CMI_2025 shows output from the core CMI_2024 v05 BETA model with a long-term rate of 1.5% pa.




CMI approach to COVID: CMI_2025



UK Male SMRs (ages 65 to 95)



UK Female SMRs (ages 65 to 95)




CMI_2025 was the first “business as usual” year under new approach. Further strengthening of projection due to light mortality in 2025.



How does the Fitted Overlay work?

Step 1: Define the Shape


Fitted Overlay Shape (Core)




- In the UK, the core model assumes the Fitted Overlay halves each year from 2020.
- However, users can also define their own shape by year and by age.

Step 2: Fit the Magnitude

Observed and fitted mortality (E&W men, ages 65-95)




- The magnitude of the fitted overlay is fitted simultaneously alongside age, period and cohort effects within the model.




What levers can we pull?

Lever 1: Pace of run off




- We can do this using the extended Half Life parameter, or by using the user-defined option in the CMI model.

Lever 2: Permanent Component




- We can define a value as an advanced parameter or by using the user-defined option.



What levers can we pull?

Lever 3: Extended peak



- By using the user-defined option, we can extend the peak or apply the peak in a later year than 2020.

Lever 4: Variation by Age

InputsOverlay: User-defined option for the fitted overlay

[Return to the "InputsMain" sheet](#)

Enter values for the run-off schedule $R(x,t)$ - the proportion of the fitted overlay that applies for each combination of age and calendar year

Age Year	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
65											
66											
67											
68											
69											
70											
71											
72											
73											
74											
75											

- Finally, we have the option to vary the fitted overlay by age as well as by year.
- We have not explored this option in the analysis presented today.


Applying the fitted overlay in different countries




Using pandemic data - exponential decay (UK)



UK Male SMRs (ages 65 to 95)



UK Female SMRs (ages 65 to 95)




In UK, core calibration of the fitted overlay assumes **exponential decay** following a **peak in 2020** with half life of **one year**.




Using pandemic data - exponential decay (US)



US Male SMRs (ages 65 to 95)



US Female SMRs (ages 65 to 95)




US prolonged peak not captured by exponential decay starting in 2020 – should we try to capture pandemic shape better?






Using pandemic data - fitted overlay (US)

US Male SMRs (ages 65 to 95)



US Female SMRs (ages 65 to 95)




How should exponential decay begin from a prolonged peak?
 Does a higher/longer peak justify assuming pandemic excess to be over sooner?






Using pandemic data - exponential decay (Canada)

Canada Male SMRs (ages 65 to 95)



Canada Female SMRs (ages 65 to 95)



Later peak not captured by exponential decay starting in 2020


Source: Club Vita calculations using CMI_2024 v05 projections model. Canadian data up to 2023 from the Human Mortality Database (www.mortality.org), 2024 data estimated using StatisticsCanada life table. Note: 1.3% long term rate of improvement is used throughout. Fitted overlay excess weightings half in each subsequent from last weighting disclosed.




Using pandemic data - fitted overlay (Canada)




Canada Male SMRs (ages 65 to 95)



Canada Female SMRs (ages 65 to 95)




Best approach will depend on view of recent data –
Is the transitory experience from the pandemic over?




Using pandemic data - exponential decay (NL)



NL Male SMRs (ages 65 to 95)



NL Female SMRs (ages 65 to 95)




Exponential decay (with one year half life) provides for a poor fit to the underlying data, particularly for women.






Using pandemic data - with extended half-life (NL)

NL Male SMRs (ages 65 to 95)



NL Female SMRs (ages 65 to 95)




Here we reflect the slow emergence from the pandemic by doubling the half-life. The fit remains poor – how else can we adjust the Fitted Overlay shape?






Using pandemic data - with permanent overlay (NL)

NL Male SMRs (ages 65 to 95)



NL Female SMRs (ages 65 to 95)




By adding a 5% permanent overlay, we can better capture year-on-year excess rates. However, this still allows for limited “bounce back” for men and none for women.



Observations

- Different options to use fitted overlay outside the UK:
 - Adjust peak
 - Model will estimate total excess better if you can capture increased mortality more accurately across the key 2020-2022 years
 - Adjust when you start running off
 - Longer period of excess from later or prolonged peak may result in jumping to a later point of run-off
 - Adjust half life
 - Lower peak may result in a slower run-off of excess
 - Add permanent overlay
 - Pandemic may have contributed to a step change in mortality




Question 3:
What happens if we just ignore the
COVID years?




Skipping the pandemic years of data (UK)


UK Male SMRs (ages 65 to 95)



UK Female SMRs (ages 65 to 95)




A plausible alternative approach?




“Skipping” the pandemic years of data (US)



US Male SMRs (ages 65 to 95)



US Female SMRs (ages 65 to 95)




A plausible alternative approach?
Will depend on your view of 2023-2024 data.




“Skipping” the pandemic years of data (Canada)



Canada Male SMRs (ages 65 to 95)



Canada Female SMRs (ages 65 to 95)



A plausible alternative approach?
Will depend on your view of 2023-2024 data.


Source: Club Vita calculations using CMI_2024 v05 projections model. Canadian data up to 2023 from the Human Mortality Database (www.mortality.org), 2024 data estimated using [StatisticsCanada life table](https://www150.statcan.gc.ca/n1/pub/82-625-x/2024001/article/00001-eng.htm). Note: 1.3% long term rate of improvement is used throughout




“Skipping” the pandemic years of data (NL)



NL Male SMRs (ages 65 to 95)



NL Female SMRs (ages 65 to 95)




This approach will lead to negative short-term improvements for women.



Observations

- “Skipping” pandemic years of data could be an alternative approach
- Need to have a few years of post-pandemic data with some continuity from 2019 mortality
- Appropriateness will depend on judgement of signal in emerging years’ data




What are the most plausible approaches?


Summary (UK)



UK Male SMRs (ages 65 to 95)



UK Female SMRs (ages 65 to 95)




Could a light 2026 lead to a full reversion to the pre-COVID trend?
The CMI_2024+ model is well placed to adapt to the emerging signal.




Summary (US)



US Male SMRs (ages 65 to 95)




US Female SMRs (ages 65 to 95)



Judgement required on outlook for excess – new years of data very important.


Source: Club Vita calculations using CMI_2024 v05 projections model. Canadian data up to 2023 from the Human Mortality Database (www.mortality.org), 2024 data estimated using [StatisticsCanada life table](http://StatisticsCanada). Note: 1.3% long term rate of improvement is used throughout. Fitted overlay excess weightings half in each subsequent from last weighting disclosed.




Summary (Canada)



Canada Male SMRs (ages 65 to 95)




Canada Female SMRs (ages 65 to 95)



Judgement required on outlook for excess – new years of data very important.


Source: Club Vita calculations using CMI_2024 v05 projections model. Canadian data up to 2023 from the Human Mortality Database (www.mortality.org), 2024 data estimated using [StatisticsCanada life table](https://www150.statcan.gc.ca/n1/pub/82-625-x/2024001/article/00001-eng.htm). Note: 1.3% long term rate of improvement is used throughout. Fitted overlay excess weightings half in each subsequent from last weighting disclosed.




Summary (Netherlands)




NL Male SMRs (ages 65 to 95)



NL Female SMRs (ages 65 to 95)



Should we interpret the post COVID data as a step change, or should we expect some reversion to the grey line in 2026+?



Further considerations




Variations in emerging trends by age.



Subpopulation considerations:
- Geographical variations in excess rates.
- Insured vs general population.



How to combine preferred projection mechanism
with base tables.



Questions?



Chair

Natalie Gleed FIA FSA

Head of Business
Development



Panellist

Erik Pickett PhD FIA FSA


Head of Actuarial
Content



Panellist

Nick Chadwick FIA

Longevity risk specialist



Thank you

This presentation contains confidential information belonging to Club VITA LLP (CV). CV are the owner or the licensee of all intellectual property rights in the presentation. All such rights are reserved. The material and charts included herewith are provided as background information for illustration purposes only. This presentation is not a definitive analysis of the subjects covered and should not be regarded as a substitute for specific advice in relation to the matters addressed. It is not advice and should not be relied upon. This presentation should not be released or otherwise disclosed to any third party without prior consent from CV. CV accept no liability for errors or omissions or reliance upon any statement or opinion herein.